Overview

HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma

Status:
RECRUITING

Trial end date:
2030-11-19

Target enrollment:

Participant gender:

Summary

This study will compare outcomes for M1 iCCA patients treated with and without L-RT by reviewing iCCA patients found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT.

Phase:

PHASE2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

AstraZeneca
Varian Medical Systems, Inc.

Treatments:

Cisplatin
durvalumab
Gemcitabine